Nanhua Bio Financials
| 000504 Stock | 10.07 0.09 0.89% |
Operating Margin 0.0118 | Profit Margin (0.30) | Return On Equity (0.31) |
Nanhua | Select Account or Indicator |
Understanding current and past Nanhua Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Nanhua Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Nanhua Bio's assets may result in an increase in income on the income statement.
Please note, the presentation of Nanhua Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nanhua Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Nanhua Bio's management manipulating its earnings.
Nanhua Bio Stock Summary
Nanhua Bio competes with China State, Huafa Industrial, China International, Kweichow Moutai, and Contemporary Amperex. Nanhua Bio is entity of China. It is traded as Stock on SHE exchange.Specialization | Communication Services, Media & Entertainment |
| Instrument | China Stock View All |
| Exchange | Shenzhen Stock Exchange |
| ISIN | CNE000000263 |
| Business Address | Lugu Science and |
| Sector | Media |
| Industry | Communication Services |
| Benchmark | Dow Jones Industrial |
| Website | www.landfar.cn |
| Phone | 86 73 1858 10285 |
You should never invest in Nanhua Bio without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Nanhua Stock, because this is throwing your money away. Analyzing the key information contained in Nanhua Bio's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Nanhua Bio Key Financial Ratios
Nanhua Bio's financial ratios allow both analysts and investors to convert raw data from Nanhua Bio's financial statements into concise, actionable information that can be used to evaluate the performance of Nanhua Bio over time and compare it to other companies across industries.| Revenue | 136.79 M | ||||
| Gross Profit | 127.36 M | ||||
| EBITDA | (38.19 M) | ||||
| Net Income | (28.17 M) | ||||
| Total Asset | 771.38 M |
Nanhua Bio Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 268.3M | 556.1M | 659.2M | 553.1M | 771.4M | 810.0M | |
| Other Current Liab | 51.2M | 75.8M | 398.0M | 143.0M | 11.5M | 10.9M | |
| Other Liab | 4.3M | 3.4M | 3.0M | 3.2M | 2.9M | 2.8M | |
| Accounts Payable | 15.6M | 60.7M | 89.6M | 82.0M | 82.2M | 86.3M | |
| Cash | 69.4M | 67.0M | 153.0M | 218.1M | 493.8M | 518.5M | |
| Net Receivables | 52.7M | 188.8M | 202.2M | 158.8M | 123.2M | 80.5M | |
| Inventory | 18.4M | 14.9M | 10.6M | 4.5M | 10.7M | 20.3M | |
| Other Current Assets | 1.7M | 174.5M | 150.3M | 5.4M | 7.2M | 6.9M | |
| Total Liab | 153.9M | 421.7M | 548.9M | 473.2M | 466.7M | 262.8M | |
| Other Assets | 81.8M | 45.8M | 92.1M | 86.6M | 99.6M | 140.9M | |
| Intangible Assets | 2.9M | 1.5M | 217.8K | 361.3K | 440.8K | 418.8K | |
| Retained Earnings | (445.0M) | (436.8M) | (455.9M) | (468.6M) | (531.1M) | (504.5M) | |
| Net Tangible Assets | 4.3M | 13.8M | 8.0M | 5.0M | 5.7M | 6.0M | |
| Short Long Term Debt | 50.1M | 13.0M | 32.9M | 63.1M | 28.1M | 53.3M | |
| Total Current Assets | 143.6M | 479.7M | 516.6M | 416.2M | 654.9M | 381.0M | |
| Net Invested Capital | 68.5M | 39.6M | 49.6M | 76.9M | 285.1M | 299.3M | |
| Net Working Capital | (6.0M) | 61.4M | (12.4M) | (38.9M) | 202.5M | 212.6M |
Nanhua Bio Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 8.9M | 4.0M | 14.1M | 11.9M | 10.2M | 10.7M | |
| Total Revenue | 134.2M | 175.6M | 156.6M | 200.3M | 136.8M | 117.7M | |
| Cost Of Revenue | 49.7M | 78.1M | 45.7M | 70.5M | 43.7M | 69.4M | |
| Income Before Tax | 17.4M | 19.0M | (30.2M) | (21.6M) | (44.7M) | (42.5M) | |
| Net Income | 18.8M | 8.2M | (19.1M) | (12.7M) | (28.2M) | (26.8M) | |
| Income Tax Expense | (819.5K) | 4.3M | 2.9M | 8.2M | 9.4M | 9.9M | |
| Operating Income | (13.8M) | 24.4M | 4.0M | 12.2M | (9.1M) | (8.6M) | |
| Minority Interest | 96.0M | 107.9M | 14.0M | 17.1M | 18.6M | 17.7M | |
| Tax Provision | (819.5K) | 4.3M | 2.9M | 8.2M | 2.1M | 3.2M | |
| Net Interest Income | (10.5M) | (3.3M) | (14.0M) | (11.6M) | (9.1M) | (9.6M) | |
| Interest Income | 179.4K | 138.9K | 2.5M | 1.8M | 2.3M | 2.5M | |
| Gross Profit | 84.5M | 97.5M | 110.9M | 129.8M | 93.1M | 85.0M | |
| Ebit | (12.1M) | 20.5M | (21.7M) | (19.7M) | (17.7M) | (16.9M) | |
| Research Development | 15.5M | 5.0M | 8.5M | 10.0M | 12.6M | 9.7M | |
| Ebitda | 32.0M | 26.3M | (9.2M) | (3.5M) | (4.0M) | (3.8M) |
Nanhua Bio Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Nanhua Bio Medicine. It measures of how well Nanhua is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Nanhua Bio brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Nanhua had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Nanhua Bio has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 3.0M | 3.7M | 4.3M | 4.8M | (6.2M) | (5.9M) | |
| Capital Expenditures | 2.6M | 4.5M | 32.0M | 16.9M | 5.9M | 6.1M | |
| Net Income | 18.8M | 8.2M | (19.1M) | (12.7M) | (28.2M) | (26.8M) | |
| Net Borrowings | (39M) | 192.3M | 19.9M | (73.0M) | (65.7M) | (62.4M) | |
| Change To Netincome | (21.3M) | 12.7M | 34.3M | 22.2M | 25.5M | 26.8M | |
| Investments | 2.6M | 12.5M | 167.0 | 494.6K | 12.8M | 7.5M | |
| Change In Cash | 10.4M | (2.4M) | 86.0M | 65.1M | 275.7M | 289.4M | |
| Depreciation | 5.7M | 3.4M | 6.9M | 6.2M | 6.3M | 5.4M | |
| End Period Cash Flow | 69.4M | 67.0M | 153.0M | 218.1M | 493.8M | 518.5M | |
| Free Cash Flow | 11.9M | (211.7M) | 75.1M | 149.4M | 30.4M | 31.9M | |
| Other Non Cash Items | 12.3M | 4.5M | 20.8M | 21.6M | 20.2M | 18.1M |
Nanhua Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nanhua Bio's current stock value. Our valuation model uses many indicators to compare Nanhua Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nanhua Bio competition to find correlations between indicators driving Nanhua Bio's intrinsic value. More Info.Nanhua Bio Medicine is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nanhua Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nanhua Bio's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Nanhua Bio Medicine Systematic Risk
Nanhua Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Nanhua Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Nanhua Bio Medicine correlated with the market. If Beta is less than 0 Nanhua Bio generally moves in the opposite direction as compared to the market. If Nanhua Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Nanhua Bio Medicine is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Nanhua Bio is generally in the same direction as the market. If Beta > 1 Nanhua Bio moves generally in the same direction as, but more than the movement of the benchmark.
Nanhua Bio Medicine Total Assets Over Time
Nanhua Bio November 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Nanhua Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Nanhua Bio Medicine. We use our internally-developed statistical techniques to arrive at the intrinsic value of Nanhua Bio Medicine based on widely used predictive technical indicators. In general, we focus on analyzing Nanhua Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Nanhua Bio's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.41 | |||
| Information Ratio | 0.1255 | |||
| Maximum Drawdown | 19.13 | |||
| Value At Risk | (5.46) | |||
| Potential Upside | 9.82 |
Complementary Tools for Nanhua Stock analysis
When running Nanhua Bio's price analysis, check to measure Nanhua Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanhua Bio is operating at the current time. Most of Nanhua Bio's value examination focuses on studying past and present price action to predict the probability of Nanhua Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanhua Bio's price. Additionally, you may evaluate how the addition of Nanhua Bio to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |